|
|
| (11) | Number of the document | C 2187879 |
| (68) | Number of the document | 2187879 |
| (21) | Application number for Supplementary Protection Certificate | PA 2017 014 |
| (22) | Date of filing the application | 2017-05-08 |
| (41) | Date of publication of the application | 2017-05-25 |
| Date of publication of SPC | 2018-10-25 | |
| (24) | Date of coming into effect of SPC | 2028-08-16 |
| (71) |
Boehringer Ingelheim International GmbH,
Binger Strasse 173, 55216 Ingelheim am Rhein,
DE
|
| (73) |
Boehringer Ingelheim International GmbH,
Binger Strasse 173, 55216 Ingelheim am Rhein,
DE
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (93) | EU/1/16/1146/001 - EU/1/16/1146/018, 2016-11-11 |
| (94) | 2031-11-15 |
| (95) | Empagliflozino ir linagliptino arba jo farmaciniu požiūriu priimtinos druskos derinys |
| SPC revoked (the basic patent revoked after opposition at the EPO) | ||
| Date of negative decision to issue the SPC | 2023-11-16 |